A detailed history of Ubs Asset Management Americas Inc transactions in Theravance Biopharma, Inc. stock. As of the latest transaction made, Ubs Asset Management Americas Inc holds 117,505 shares of TBPH stock, worth $1.11 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
117,505
Previous 138,877 15.39%
Holding current value
$1.11 Million
Previous $1.18 Million 19.54%
% of portfolio
0.0%
Previous 0.0%

Shares

21 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$7.66 - $10.25 $163,709 - $219,063
-21,372 Reduced 15.39%
117,505 $947,000
Q2 2024

Aug 13, 2024

BUY
$8.29 - $9.92 $616,353 - $737,542
74,349 Added 115.22%
138,877 $1.18 Million
Q4 2023

Feb 14, 2024

BUY
$8.58 - $11.4 $26,709 - $35,488
3,113 Added 5.07%
64,528 $725,000
Q1 2023

May 15, 2023

SELL
$9.87 - $11.44 $35,768 - $41,458
-3,624 Reduced 5.57%
61,415 $666,000
Q4 2022

Feb 14, 2023

SELL
$9.65 - $11.34 $71,207 - $83,677
-7,379 Reduced 10.19%
65,039 $729,000
Q2 2022

Aug 12, 2022

SELL
$8.41 - $10.34 $19,721 - $24,247
-2,345 Reduced 3.14%
72,418 $656,000
Q1 2022

May 16, 2022

BUY
$8.33 - $12.96 $5,072 - $7,892
609 Added 0.82%
74,763 $714,000
Q4 2021

Feb 14, 2022

BUY
$7.42 - $11.05 $71,632 - $106,676
9,654 Added 14.97%
74,154 $819,000
Q3 2021

Nov 15, 2021

BUY
$6.77 - $14.41 $3,919 - $8,343
579 Added 0.91%
64,500 $477,000
Q2 2021

Aug 16, 2021

BUY
$14.52 - $22.46 $45,404 - $70,232
3,127 Added 5.14%
63,921 $928,000
Q4 2020

Mar 01, 2021

BUY
$14.89 - $20.16 $258,579 - $350,098
17,366 Added 39.99%
60,794 $1.08 Million
Q2 2020

Aug 14, 2020

BUY
$20.64 - $30.69 $198,639 - $295,360
9,624 Added 28.47%
43,428 $911,000
Q1 2020

May 15, 2020

BUY
$17.84 - $31.21 $838 - $1,466
47 Added 0.14%
33,804 $781,000
Q4 2019

Feb 14, 2020

BUY
$16.12 - $25.89 $111,743 - $179,469
6,932 Added 25.84%
33,757 $873,000
Q3 2019

Nov 14, 2019

BUY
$16.51 - $23.78 $226,120 - $325,690
13,696 Added 104.32%
26,825 $522,000
Q1 2019

May 14, 2019

SELL
$22.57 - $28.15 $163,587 - $204,031
-7,248 Reduced 35.57%
13,129 $0
Q4 2018

Feb 13, 2019

BUY
$22.52 - $35.07 $69,812 - $108,717
3,100 Added 17.94%
20,377 $521,000
Q3 2018

Nov 14, 2018

BUY
$22.83 - $32.67 $186,247 - $266,521
8,158 Added 89.46%
17,277 $0
Q1 2018

May 14, 2018

SELL
$23.37 - $29.71 $185,978 - $236,432
-7,958 Reduced 46.6%
9,119 $0
Q4 2017

Feb 09, 2018

SELL
$25.82 - $35.66 $178,700 - $246,802
-6,921 Reduced 28.84%
17,077 $0
Q3 2017

Nov 13, 2017

BUY
$23.88 - $34.96 $573,072 - $838,970
23,998
23,998 $0

Others Institutions Holding TBPH

About Theravance Biopharma, Inc.


  • Ticker TBPH
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 66,782,400
  • Market Cap $632M
  • Description
  • Theravance Biopharma, Inc., a biopharmaceutical company, discovers, develops, and commercializes respiratory medicines in the United States, Europe, and Asia. The company offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist used for the treatment of chronic obstructive pulmonary disease (COPD). Its product portfolio also inc...
More about TBPH
Track This Portfolio

Track Ubs Asset Management Americas Inc Portfolio

Follow Ubs Asset Management Americas Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Asset Management Americas Inc, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Asset Management Americas Inc with notifications on news.